News and Press Releases

Acuitas Therapeutics to Showcase LNP Delivery Platform at Four Prestigious Conferences in November 2025

29 October 2025 -- British Columbia, Canada -- Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, today announced its participation in four upcoming conferences in November 2025....

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 11, 2025

6190 Agronomy Road, Suite 205. Vancouver, BC V6T 1Z3

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Immune response successfully improved with second generation vaccine candidate4 November 2025 -- Saint-Herblain, France -- Valneva SE, a specialty vaccine company, today announced positive results of its Phase 1 clinical...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: November 4, 2025

6 rue Alain Bombard, 44800 Saint-Herblain, France

Naobios and Tokyo Metropolitan Institute of Medical Science partner to develop new live-attenuated vaccine against mpox

 Partnership aims to commercialize new mpox vaccine - with higher level of safety - by 2027 23 October 2025 -- Nantes, France, and Tokyo, Japan -- Naobios, a CDMO (Contract Development...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 23, 2025

Operating office 6 rue Alain Bombard 44800 Saint-Herblain

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 15, 2025

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa

Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV 10 October 2025 -- Cairo, Egypt; Berlin, Germany; and New York, New York -- IAVI,...

Category: Biotechnology, Drug Delivery, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 10, 2025

Herbert-Bayer-Straße 8 13086 Berlin

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 6, 2025

7-11 Boulevard Haussmann 75009 Paris

Evonik and Ethris enter strategic partnership to expand offerings for nucleic acid delivery

Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic Accelerating RNA-based therapeutic solutions for customers through...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2025

Bavarian Nordic launches VIMKUNYA in the UK for the Prevention of Chikungunya, for individuals aged 12 years and older

3 September 2025 -- London, UK -- Bavarian Nordic A/S announced today the official UK launch of the VIMKUNYA® chikungunya vaccine (recombinant, absorbed). This follows the recent approval by the...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 3, 2025

Bavarian Nordic GmbH Fraunhoferstrasse 13 D-82152 Martinsried

Leqembi ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment The...

Category: Other, Pharmaceutical
Posted: April 30, 2025

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma 

Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

980 Great West Rd, London TW8 9GS

Moderna’s UK Manufacturing Facility Receives Manufacturing Licence from the MHRA

Milestone marks a pivotal step toward producing mRNA vaccines in the UK in 2025 15 April 2025 – London, UK – ACCESS WIRE – Moderna, Inc. (NASDAQ: MRNA) today announced...

Category: Manufacturing and Packing
Posted: April 15, 2025

Global Headquarters 200 Technology Square Cambridge, MA 02139

Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulatorfor the Treatment of Cystic Fibrosis

Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

UK’s MHRA grants Promising Innovative Medicine designation to argenx’ investigational therapy, subcutaneous efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)

28 November 2024 -- Gerrards Cross, UK -- argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, confirmed today that its investigational...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 28, 2024

Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

Valneva Scotland Receives Prestigious Award for Health and Safety Excellence

8 August 2024 -- Scotland, UK -- Scotland's largest vaccine producer, Valneva Scotland Ltd, based in Livingston, has achieved an esteemed Silver Award for health and safety from the Royal...

Category: BioManufacturing, Pharmaceutical
Posted: August 9, 2024

6 rue Alain Bombard, 44800 Saint-Herblain, France

Europe 2024 World Vaccine Congress

23 July 2024, Barcelona, Spain – World Vaccine Congress Europe will host 3000+ attendees, 280 speakers, 150+ exhibitors and plenty of start-ups over the course of 4 days. With a...

Category: Drug Delivery, Other
Posted: July 23, 2024